Sarepta shares more Elevidys safety data in response to patient group's FDA petition
18th August 2025 Uncategorised 0Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy patient group petitions the FDA to update the medicine’s label.
More: Sarepta shares more Elevidys safety data in response to patient group's FDA petition
Source: fierce